Compare TG Therapeutics Inc (TGTX) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Unity Software Inc — how do they compare? TG Therapeutics Inc trades at $49.65 (market cap $7.53B), while Unity Software Inc trades at $43.64 (market cap $18.97B). The key difference: Unity Software Inc is far larger — about 2.5× TG Therapeutics Inc's market cap, and Unity Software Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | U | |
|---|---|---|
Market Cap | $7.53B | $18.97B |
Sector | Health | Technology |
52-Week High | $59.06 | $49.47 |
52-Week Low | $26.94 | $17.13 |
Enterprise Value | $7.73B | $18.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.76, up 0.42% in the last session, with a bearish technical signal from moving averages. Recent earnings missed estimates, but revenue growth is strong, driven by BRIUMVI sales, with 2026 guidance raised to $950 million. The stock faces near-term pressure from earnings underperformance and a legal investigation into potential fiduciary breaches.
The outlook is mixed: strong revenue momentum and a high analyst buy rating (84.62%) support upside to the $63.75 consensus target, but risks include earnings volatility, high valuation multiples, and legal overhangs. Investors should weigh robust growth prospects against execution and sentiment challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
